GlassScriptPhysician profile
Michael V Genuardi
NPI 1275897746
$7,035.22
in general payments reported to CMS, 2019-2025
9 companies · $270 in 2025
The $270 reported for 2025 was less than what a typical Advanced Heart Failure and Transplant Cardiology provider received nationally (typical 2025 total: $1,046).
See the full distribution for Advanced Heart Failure and Transplant Cardiology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,172 · 2020: $377 · 2021: $1,285 · 2022: $841 · 2023: $385 · 2024: $1,704 · 2025: $270.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,368 · Food and Beverage: $992.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,367.54 |
| Food and Beverage | $991.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $5,133.11 | 2019-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems |
| Zoll Respicardia, INC. | $1,225.00 | 2021-2022 | |
| Cvrx, INC. | $270.37 | 2024-2025 | Barostim Neo System |
| Medtronic Vascular, INC. | $140.17 | 2019 | |
| Alnylam Pharmaceuticals INC. | $125.47 | 2025 | Amvuttra |
| Abiomed | $70.70 | 2022-2023 | Impella |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $32.92 | 2020-2023 | Lifevest |
| Philips North America LLC | $19.93 | 2023 | |
| Novartis Pharmaceuticals Corporation | $17.55 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Genuardi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.